Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colloidal oatmeal is a finely ground powder made from whole oats (Avena sativa) that is dispersed in water to form a suspension. It is rich in beta-glucan, avenanthramides (oat phenols), vitamin E, linoleic acid, and oleic acid. These components provide anti-inflammatory and antioxidant effects and help restore the skin barrier. Colloidal oatmeal acts as a skin protectant by forming a physical barrier on the skin surface to lock in moisture and reduce transepidermal water loss. It soothes itching and irritation associated with conditions such as eczema (atopic dermatitis), dry or sensitive skin, rashes from poison ivy/oak/sumac, insect bites, psoriasis, and other minor irritations. The US FDA recognizes colloidal oatmeal as an over-the-counter (OTC) active ingredient for temporary protection and relief of minor skin irritations[1][2][5]. Clinical studies have shown its efficacy in improving symptoms of mild-to-moderate atopic dermatitis[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colloidal oatmeal.